Fulcrum Therapeutics (FULC) EPS (Basic) (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly EPS (Basic) of -$0.46 for Q2 2026, down 65.88% year-over-year from -$1.34 in Q2 2025, and up 30.03% quarter-over-quarter from -$0.66 in Q1 2026.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) EPS (Basic) (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported EPS (Basic) for 9 consecutive years, with -$0.46 the latest figure, recorded in Q2 2026.
- In Q2 2026, EPS (Basic) fell 65.88% year-over-year to -$0.46; the TTM figure through Jun 2026 stood at -$2.47 (down 65.6% YoY), while the FY2025 annual figure was -$2544.9, down 114.95% from the prior year.
- EPS (Basic) improved to -$0.46 in Q2 2026 per FULC's latest filing, from -$0.66 in the prior quarter.
- Across five years, EPS (Basic) topped out at $0.89 in Q2 2024 and bottomed at -$1328.3 in Q4 2025.
- Historically, EPS (Basic) has averaged -$428.53 across 5 years, with a median of -$386.68 in 2023.
- Annual changes were most pronounced in 2023 — EPS (Basic) plunged 30210.29% — and 2024, when it jumped 100.23%.
- Fulcrum Therapeutics' EPS (Basic) stood at -$663.65 in 2022, then declined by 5.94% to -$703.08 in 2023, then jumped by 42.56% to -$403.84 in 2024, then tumbled by 228.91% to -$1328.3 in 2025, then surged by 99.97% to -$0.46 in 2026.
- Business Quant data shows FULC's EPS (Basic) at -$0.46 in Q2 2026, -$0.66 in Q1 2026, and -$1328.3 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | Fulcrum Therapeutics | 293.24 Mn | 293.24 Mn | - | -0.34 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.34 |
| Mar 31, 2026 | -0.30 |
| Dec 31, 2025 | -0.32 |
| Sep 30, 2025 | -0.31 |
| Jun 30, 2025 | -0.28 |
| Mar 31, 2025 | -0.33 |
| Dec 31, 2024 | -0.27 |
| Sep 30, 2024 | -0.35 |
| Jun 30, 2024 | 0.89 |
| Mar 31, 2024 | -0.49 |
| Dec 31, 2023 | -0.40 |
| Sep 30, 2023 | -0.39 |
| Jun 30, 2023 | -0.38 |
| Mar 31, 2023 | -0.47 |
| Dec 31, 2022 | -0.58 |
| Sep 30, 2022 | -0.51 |
| Jun 30, 2022 | -0.84 |
| Mar 31, 2022 | -0.66 |
| Dec 31, 2021 | -0.68 |
| Sep 30, 2021 | -0.57 |